Semin Reprod Med 2021; 39(01/02): 034-061
DOI: 10.1055/s-0041-1729763
Review Article

The Pathophysiology of Hypercoagulability and Infertility

Ann Kinga Malinowski
1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynaecology, Sinai Health System, Toronto, Canada
2   Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada
3   Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Canada
› Author Affiliations

Abstract

Alongside an interplay of a multitude of factors, attainment of a favorable pregnancy outcome is predicated on successful implantation, which in itself is a complex process anchored by balanced interchange with the hemostatic system. Among other etiologies, failure of implantation can result in infertility, and lead affected couples to consider assisted reproductive technology (ART) in an effort to fulfill their desire for procreation. Given the critical role of the hemostatic system in the process of implantation, documentation of a hypercoagulable state during controlled ovarian stimulation in the context of in vitro fertilization, as well as the potential association of its derangement in the setting of thrombophilia, with infertility, ART, ovarian hyperstimulation syndrome, and failure of implantation are explored. Additionally, current evidence addressing the relationship between ART and thromboembolism is examined, as is the role of therapy with heparin and aspirin to decrease thrombotic risk and improve ART-related pregnancy outcomes. Evidence-based recommendations from relevant professional societies are summarized.



Publication History

Article published online:
17 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Shaulov T, Sierra S, Sylvestre C. Recurrent implantation failure in IVF: a Canadian Fertility and Andrology Society Clinical Practice Guideline. 2020 . cited October 17, 2020. Accessed March 10, 2021 at: https://www.ncbi.nlm.nih.gov/pubmed/32962928
  • 2 Kuperman A, Di Micco P, Brenner B. Fertility, infertility and thrombophilia. Womens Health (Lond) 2011; 7 (05) 545-553
  • 3 Ivanov P, Tsvyatkovska T, Konova E, Komsa-Penkova R. Inherited thrombophilia and IVF failure: the impact of coagulation disorders on implantation process. Am J Reprod Immunol 2012; 68 (03) 189-198
  • 4 Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007; 33 (01) 111-117
  • 5 Gerotziafas GT, Van Dreden P, Mathieu d'Argent E. et al. Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study. Thromb J 2017; 15: 9
  • 6 Krikun G, Lockwood CJ, Paidas MJ. Tissue factor and the endometrium: from physiology to pathology. Thromb Res 2009; 124 (04) 393-396
  • 7 Macklon NS, Geraedts JP, Fauser BC. Conception to ongoing pregnancy: the ‘black box’ of early pregnancy loss. Hum Reprod Update 2002; 8 (04) 333-343
  • 8 Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2020; 113 (03) 533-535
  • 9 Chandra A, Copen CE, Stephen EH. Infertility and impaired fecundity in the United States 1982–2010: data from the National Survey of Family Growth. National Health Statistics Reports; No. 67. Hyattsville, MD: National Center for Health Statistics; 2020
  • 10 Zegers-Hochschild F, Adamson GD, Dyer S. et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril 2017; 108 (03) 393-406
  • 11 Khizroeva J, Makatsariya A, Bitsadze V, Makatsariya N, Khamani N. In vitro fertilization outcomes in women with antiphospholipid antibodies circulation. J Matern Fetal Neonatal Med 2020; 33 (12) 1988-1993
  • 12 Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol 2012; 10: 32
  • 13 Gómez R, Soares SR, Busso C, Garcia-Velasco JA, Simón C, Pellicer A. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med 2010; 28 (06) 448-457
  • 14 Todros T, Carmazzi CM, Bontempo S, Gaglioti P, Donvito V, Massobrio M. Spontaneous ovarian hyperstimulation syndrome and deep vein thrombosis in pregnancy: case report. Hum Reprod 1999; 14 (09) 2245-2248
  • 15 Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org, Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016; 106 (07) 1634-1647
  • 16 Al-Sadawi M, Chowdhury R, Asun S. et al. Ovarian hyperstimulation syndrome and myocardial infarction: a systematic review. Int J Clin Endocrinol Metab 2019; 5 (01) 009-012
  • 17 Coughlan C, Ledger W, Wang Q. et al. Recurrent implantation failure: definition and management. Reprod Biomed Online 2014; 28 (01) 14-38
  • 18 Society for Assisted Reproductive Technology (SART). SART National Summary Report 2017. cited October 19, 2020. Accessed March 10, 2021 at: https://www.sartcorsonline.com/rptCSR_PublicMultYear.aspx?reportingYear=2017
  • 19 Canadian Assisted Reproductive Technologies Register Plus (CARTR Plus). CARTR Plus 2018 Report. 2019 . cited October 19, 2020. Accessed March 10, 2021 at: https://cfas.ca/_Library/CARTR/CFAS_CARTR_Plus_presentation_plenary_slides_FINAL_for_website_-_opened.pdf
  • 20 De Geyter C, Calhaz-Jorge C, Kupka MS. et al; European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). ART in Europe, 2014: results generated from European registries by ESHRE: the European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2018; 33 (09) 1586-1601
  • 21 Bashiri A, Halper KI, Orvieto R. Recurrent implantation failure-update overview on etiology, diagnosis, treatment and future directions. Reprod Biol Endocrinol 2018; 16 (01) 121
  • 22 Di Micco P, D'Uva M, Strina I. et al. The role of D-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia induced sterility. J Transl Med 2004; 2 (01) 38
  • 23 Behjati R, Modarressi MH, Jeddi-Tehrani M. et al. Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. Ann Hematol 2006; 85 (04) 268-271
  • 24 Coulam CB, Jeyendran RS. Thrombophilic gene polymorphisms are risk factors for unexplained infertility. Fertil Steril 2009; 91 (4, Suppl): 1516-1517
  • 25 Bianca S, Barrano B, Cutuli N. et al. Unexplained infertility and inherited thrombophilia. Fertil Steril 2009; 92 (01) e4 , author reply e5
  • 26 Fatini C, Conti L, Turillazzi V. et al. Unexplained infertility: association with inherited thrombophilia. Thromb Res 2012; 129 (05) e185-e188
  • 27 Casadei L, Puca F, Privitera L, Zamaro V, Emidi E. Inherited thrombophilia in infertile women: implication in unexplained infertility. Fertil Steril 2010; 94 (02) 755-757
  • 28 Schwarze JM, Albornoz C. C A. Relación de trombofilia con infertilidad y pronóstico reproductivo en técnicas de reproducción asistida de alta complejidad. Revisión sistemática. Rev Chil Obstet Ginecol 2011; 76: 230-235
  • 29 Aune B, Høie KE, Oian P, Holst N, Osterud B. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state?. Hum Reprod 1991; 6 (07) 925-927
  • 30 Coulam CB, Jeyendran RS, Fishel LA, Roussev R. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55 (05) 360-368
  • 31 Martinelli I, Taioli E, Ragni G. et al. Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88 (07) 789-793
  • 32 Qublan H, Amarin Z, Dabbas M. et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb) 2008; 11 (04) 246-253
  • 33 Qublan HS, Eid SS, Ababneh HA. et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod 2006; 21 (10) 2694-2698
  • 34 Simur A, Ozdemir S, Acar H. et al. Repeated in vitro fertilization failure and its relation with thrombophilia. Gynecol Obstet Invest 2009; 67 (02) 109-112
  • 35 Stern C, Chamley L, Norris H, Hale L, Baker HW. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2003; 80 (02) 376-383
  • 36 Buckingham KL, Chamley LW. A critical assessment of the role of antiphospholipid antibodies in infertility. J Reprod Immunol 2009; 80 (1-2): 132-145
  • 37 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  • 38 Yelnik CM, Laskin CA, Porter TF. et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 2016; 3 (01) e000131
  • 39 De Carolis S, Tabacco S, Rizzo F. et al. Antiphospholipid syndrome: an update on risk factors for pregnancy outcome. Autoimmun Rev 2018; 17 (10) 956-966
  • 40 Chighizola CB, Raimondo MG, Meroni PL. Does APS impact women's fertility?. Curr Rheumatol Rep 2017; 19 (06) 33
  • 41 Chighizola CB, de Jesus GR. Antiphospholipid antibodies and infertility. Lupus 2014; 23 (12) 1232-1238
  • 42 Birdsall MA, Lockwood GM, Ledger WL, Johnson PM, Chamley LW. Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod 1996; 11 (06) 1185-1189
  • 43 Fisch B, Fried S, Manor Y, Ovadia J, Witz IP, Yron I. Increased antiphospholipid antibody activity in in-vitro fertilization patients is not treatment-dependent but rather an inherent characteristic of the infertile state. Am J Reprod Immunol 1995; 34 (06) 370-374
  • 44 Delgado Alves J, Radway-Bright EL, Lee S. et al. Antiphospholipid antibodies are induced by in vitro fertilization and correlate with paraoxonase activity and total antioxidant capacity of plasma in infertile women. Lupus 2005; 14 (05) 373-380
  • 45 Fisch B, Rikover Y, Shohat L. et al. The relationship between in vitro fertilization and naturally occurring antibodies: evidence for increased production of antiphospholipid autoantibodies. Fertil Steril 1991; 56 (04) 718-724
  • 46 Chighizola CB, de Jesus GR, Branch DW. The hidden world of anti-phospholipid antibodies and female infertility: a literature appraisal. Autoimmun Rev 2016; 15 (06) 493-500
  • 47 Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica 2020; 105 (03) 562-572
  • 48 Practice Committee of American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril 2008; 90: S172-S173
  • 49 Romagnuolo I, Sticchi E, Fedi S. et al. Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction?. Blood Coagul Fibrinolysis 2014; 25 (03) 254-258
  • 50 Brummel-Ziedins KE, Gissel M, Francis C, Queenan J, Mann KG. The effect of high circulating estradiol levels on thrombin generation during in vitro fertilization. Thromb Res 2009; 124 (04) 505-507
  • 51 Fatini C, Mannini L, Sticchi E. et al. Hemorheologic profile in healthy women undergoing controlled ovarian stimulation. Fertil Steril 2011; 95 (01) 327-329
  • 52 Westerlund E, Henriksson P, Wallén H, Hovatta O, Wallberg KR, Antovic A. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res 2012; 130 (04) 649-653
  • 53 Harnett MJ, Bhavani-Shankar K, Datta S, Tsen LC. In vitro fertilization-induced alterations in coagulation and fibrinolysis as measured by thromboelastography. Anesth Analg 2002; 95 (04) 1063-1066 [table of contents]
  • 54 Zohav E, Almog B, Cohen A. et al. A new perspective on the risk of hypercoagulopathy in ovarian hyperstimulation syndrome using thromboelastography. Reprod Sci 2017; 24 (12) 1600-1606
  • 55 Orbach-Zinger S, Eidelman LA, Lutsker A, Oron G, Fisch B, Ben-Haroush A. The effect of in vitro fertilization on coagulation parameters as measured by thromboelastogram. Eur J Obstet Gynecol Reprod Biol 2016; 201: 118-120
  • 56 Magnani B, Tsen L, Datta S, Bader A. In vitro fertilization. Do short-term changes in estrogen levels produce increased fibrinolysis?. Am J Clin Pathol 1999; 112 (04) 485-491
  • 57 Sticchi E, Romagnuolo I, Cellai AP. et al. Fibrinolysis alterations in infertile women during controlled ovarian stimulation: influence of BMI and genetic components. Thromb Res 2012; 130 (06) 919-924
  • 58 Rice VC, Richard-Davis G, Saleh AA. et al. Fibrinolytic parameters in women undergoing ovulation induction. Am J Obstet Gynecol 1993; 169 (06) 1549-1553
  • 59 Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril 1996; 66 (03) 417-424
  • 60 Rogolino A, Coccia ME, Fedi S. et al. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood Coagul Fibrinolysis 2003; 14 (03) 277-282
  • 61 Beck-Fruchter R, Gavish I, Baram S, Geslevich Y, Weiss A. Increased coagulation index as measured by thromboelastography during ovarian stimulation for in vitro fertilization: influence of the final oocyte maturation triggering agent. Eur J Obstet Gynecol Reprod Biol 2018; 223: 26-29
  • 62 Cohen Y, Tulandi T, Almog B. et al. Prolonged activation of the coagulation system during in vitro fertilization cycles. Eur J Obstet Gynecol Reprod Biol 2017; 216: 111-115
  • 63 Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg 2009; 108 (03) 734-742
  • 64 Cotton BA, Minei KM, Radwan ZA. et al. Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients. J Trauma Acute Care Surg 2012; 72 (06) 1470-1475 , discussion 1475–1477
  • 65 McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100 (06) 1576-1583
  • 66 D'Uva M, Di Micco P, Strina I. et al. Hyperhomocysteinemia in women with unexplained sterility or recurrent early pregnancy loss from Southern Italy: a preliminary report. Thromb J 2007; 5: 10
  • 67 Ricci G, Bogatti P, Fischer-Tamaro L. et al. Factor V Leiden and prothrombin gene G20210A mutation and in vitro fertilization: prospective cohort study. Hum Reprod 2011; 26 (11) 3068-3077
  • 68 Younis JS, Ben-Ami M, Izhaki I, Jadaon J, Brenner B, Sarig G. The association between poor ovarian response and thrombophilia in assisted reproduction. Eur J Obstet Gynecol Reprod Biol 2013; 166 (01) 65-69
  • 69 Grandone E, Villani M, Tiscia GL. et al. Clinical pregnancies and live births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening. Thromb Res 2014; 133 (02) 168-172
  • 70 Patounakis G, Bergh E, Forman EJ. et al. Multiple thrombophilic single nucleotide polymorphisms lack a significant effect on outcomes in fresh IVF cycles: an analysis of 1717 patients. J Assist Reprod Genet 2016; 33 (01) 67-73
  • 71 Steinvil A, Raz R, Berliner S. et al. Association of common thrombophilias and antiphospholipid antibodies with success rate of in vitro fertilisation. Thromb Haemost 2012; 108 (06) 1192-1197
  • 72 Göpel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Möller J. Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet 2001; 358 (9289): 1238-1239
  • 73 Rudick B, Su HI, Sammel MD, Kovalevsky G, Shaunik A, Barnhart K. Is factor V Leiden mutation a cause of in vitro fertilization failure?. Fertil Steril 2009; 92 (04) 1256-1259
  • 74 Dulitzky M, Cohen SB, Inbal A. et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril 2002; 77 (03) 463-467
  • 75 Fábregues F, Tàssies D, Reverter JC, Carmona F, Ordinas A, Balasch J. Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening. Fertil Steril 2004; 81 (04) 989-995
  • 76 McDonough PG. Estrogen levels and thrombophilia-an intervening variable or a confounder?. Fertil Steril 2002; 78 (04) 889-890
  • 77 Machac S, Lubusky M, Prochazka M, Streda R. Prevalence of inherited thrombophilia in patients with severe ovarian hyperstimulation syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150 (02) 289-292
  • 78 Torry DS, Leavenworth J, Chang M. et al. Angiogenesis in implantation. J Assist Reprod Genet 2007; 24 (07) 303-315
  • 79 Boudjenah R, Molina-Gomes D, Wainer R, de Mazancourt P, Selva J, Vialard F. The vascular endothelial growth factor (VEGF) +405 G/C polymorphism and its relationship with recurrent implantation failure in women in an IVF programme with ICSI. J Assist Reprod Genet 2012; 29 (12) 1415-1420
  • 80 Goodman C, Jeyendran RS, Coulam CB. P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. Fertil Steril 2009; 92 (02) 494-498
  • 81 Vlachadis N, Tsamadias V, Vrachnis N. et al. Associations of combined polymorphisms of the platelet membrane glycoproteins Ia and IIIa and the platelet-endothelial cell adhesion molecule-1 and P-selectin genes with IVF implantation failures. J Obstet Gynaecol 2017; 37 (03) 363-369
  • 82 Azem F, Many A, Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19 (02) 368-370
  • 83 Grandone E, Colaizzo D, Lo Bue A, Checola MG, Cittadini E, Margaglione M. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001; 76 (01) 201-202
  • 84 Safdarian L, Najmi Z, Aleyasin A, Aghahosseini M, Rashidi M, Asadollah S. Recurrent IVF failure and hereditary thrombophilia. Iran J Reprod Med 2014; 12 (07) 467-470
  • 85 Vaquero E, Lazzarin N, Caserta D. et al. Diagnostic evaluation of women experiencing repeated in vitro fertilization failure. Eur J Obstet Gynecol Reprod Biol 2006; 125 (01) 79-84
  • 86 Bellver J, Soares SR, Alvarez C. et al. The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. Hum Reprod 2008; 23 (02) 278-284
  • 87 Ricci G, Simeone R. Thrombophilic screening in clinical practice should be evidence-based. Hum Reprod 2008; 23 (11) 2609 , author reply 2610–2611
  • 88 Di Nisio M, Rutjes AW, Ferrante N, Tiboni GM, Cuccurullo F, Porreca E. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood 2011; 118 (10) 2670-2678
  • 89 Hornstein MD, Davis OK, Massey JB, Paulson RJ, Collins JA. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73 (02) 330-333
  • 90 Martínez-Zamora MA, Creus M, Tassies D. et al. Reduced plasma fibrinolytic potential in patients with recurrent implantation failure after IVF and embryo transfer. Hum Reprod 2011; 26 (03) 510-516
  • 91 Sarto A, Rocha M, Martínez M, Sergio Pasqualini R. [Hypofibrinolysis and other hemostatic defects in women with antecedents of early reproductive failure]. Medicina (B Aires) 2000; 60 (04) 441-447
  • 92 Nelson SM. Prophylaxis of VTE in women - during assisted reproductive techniques. Thromb Res 2009; 123 (Suppl. 03) S8-S15
  • 93 Di Micco P, Russo V, Mastroiacovo D, Bosevski M, Lodigiani C. In vitro fertilization procedures with embryo transfer and their association with thrombophilia, thrombosis and early antithrombotic treatments. J Blood Med 2020; 11: 185-190
  • 94 Chan WS, Ginsberg JS. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the ‘ART’ behind the clot. J Thromb Haemost 2006; 4 (08) 1673-1677
  • 95 Henriksson P, Westerlund E, Wallén H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization. Obstet Anesthes Dig 2014; 34: 22-23
  • 96 Sennström M, Rova K, Hellgren M. et al. Thromboembolism and in vitro fertilization - a systematic review. Acta Obstet Gynecol Scand 2017; 96 (09) 1045-1052
  • 97 Ruopp MD, Collins TC, Whitcomb BW, Schisterman EF. Evidence of absence or absence of evidence? A reanalysis of the effects of low-dose aspirin in in vitro fertilization. Fertil Steril 2008; 90 (01) 71-76
  • 98 Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril 2012; 97 (01) 95-100
  • 99 Hansen AT, Kesmodel US, Juul S, Hvas AM. No evidence that assisted reproduction increases the risk of thrombosis: a Danish national cohort study. Hum Reprod 2012; 27 (05) 1499-1503
  • 100 Villani M, Dentali F, Colaizzo D. et al. Pregnancy-related venous thrombosis: comparison between spontaneous and ART conception in an Italian cohort. BMJ Open 2015; 5 (10) e008213
  • 101 Hansen AT, Kesmodel US, Juul S, Hvas AM. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod 2014; 29 (03) 611-617
  • 102 Grandone E, Di Micco PP, Villani M. et al; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE registry. Thromb Haemost 2018; 118 (11) 1962-1968
  • 103 Udell JA, Lu H, Redelmeier DA. Long-term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol 2013; 62 (18) 1704-1712
  • 104 Udell JA, Lu H, Redelmeier DA. Failure of fertility therapy and subsequent adverse cardiovascular events. CMAJ 2017; 189 (10) E391-E397
  • 105 Dayan N, Filion KB, Okano M. et al. Cardiovascular risk following fertility therapy: systematic review and meta-analysis. J Am Coll Cardiol 2017; 70 (10) 1203-1213
  • 106 Villani M, Favuzzi G, Totaro P. et al. Venous thromboembolism in assisted reproductive technologies: comparison between unsuccessful versus successful cycles in an Italian cohort. J Thromb Thrombolysis 2018; 45 (02) 234-239
  • 107 Filipovic-Pierucci A, Gabet A, Deneux-Tharaux C, Plu-Bureau G, Olié V. Arterial and venous complications after fertility treatment: a French nationwide cohort study. Eur J Obstet Gynecol Reprod Biol 2019; 237: 57-63
  • 108 Grandone E, Colaizzo D, Vergura P. et al. Age and homocysteine plasma levels are risk factors for thrombotic complications after ovarian stimulation. Hum Reprod 2004; 19 (08) 1796-1799
  • 109 Prandoni P, Polistena P, Bernardi E. et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157 (01) 57-62
  • 110 Delvigne A, Demoulin A, Smitz J. et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. Hum Reprod 1993; 8 (09) 1353-1360
  • 111 Abramov Y, Elchalal U, Schenker JG. Obstetric outcome of in vitro fertilized pregnancies complicated by severe ovarian hyperstimulation syndrome: a multicenter study. Fertil Steril 1998; 70 (06) 1070-1076
  • 112 Shmorgun D, Claman P, Gysler M. et al; Joint SOGC-CFAS Clinical Practice Guidelines Committee. The diagnosis and management of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 2011; 33 (11) 1156-1162
  • 113 Danolić D, Kasum M, Puljiz M. et al. The risk of hypercoagulability in ovarian hyperstimulation syndrome. Acta Clin Croat 2015; 54 (02) 186-192
  • 114 Salomon O, Schiby G, Heiman Z. et al. Combined jugular and subclavian vein thrombosis following assisted reproductive technology--new observation. Fertil Steril 2009; 92 (02) 620-625
  • 115 Gbaguidi X, Janvresse A, Benichou J, Cailleux N, Levesque H, Marie I. Internal jugular vein thrombosis: outcome and risk factors. QJM 2011; 104 (03) 209-219
  • 116 Bauersachs RM, Manolopoulos K, Hoppe I, Arin MJ, Schleussner E. More on: the ‘ART’ behind the clot: solving the mystery. J Thromb Haemost 2007; 5 (02) 438-439
  • 117 Ge SQ, Tao X, Cai LS, Deng XY, Hwang MF, Wang CL. Associations of hormonal contraceptives and infertility medications on the risk of venous thromboembolism, ischemic stroke, and cardiovascular disease in women. J Investig Med 2019; 67 (04) 729-735
  • 118 Wormer KC, Jangda AA, El Sayed FA, Stewart KI, Mumford SL, Segars JH. Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: a systematic review and cost analysis. Eur J Obstet Gynecol Reprod Biol 2018; 224: 117-124
  • 119 Kuo HC, Hsu CC, Wang ST, Huang KE. Aspirin improves uterine blood flow in the peri-implantation period. J Formos Med Assoc 1997; 96 (04) 253-257
  • 120 Wada I, Hsu CC, Williams G, Macnamee MC, Brinsden PR. The benefits of low-dose aspirin therapy in women with impaired uterine perfusion during assisted conception. Hum Reprod 1994; 9 (10) 1954-1957
  • 121 Gelbaya TA, Kyrgiou M, Li TC, Stern C, Nardo LG. Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2007; 13 (04) 357-364
  • 122 Khairy M, Banerjee K, El-Toukhy T, Coomarasamy A, Khalaf Y. Aspirin in women undergoing in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril 2007; 88 (04) 822-831
  • 123 Groeneveld E, Broeze KA, Lambers MJ. et al; IPD MARIA Study Group. Is aspirin effective in women undergoing in vitro fertilization (IVF)? Results from an individual patient data meta-analysis (IPD MA). Hum Reprod Update 2011; 17 (04) 501-509
  • 124 Dentali F, Ageno W, Rezoagli E. et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10 (10) 2075-2085
  • 125 Siristatidis CS, Basios G, Pergialiotis V, Vogiatzi P. Aspirin for in vitro fertilisation. Cochrane Database Syst Rev 2016; 11: CD004832
  • 126 Wang L, Huang X, Li X. et al. Efficacy evaluation of low-dose aspirin in IVF/ICSI patients evidence from 13 RCTs: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96 (37) e7720
  • 127 Akhtar MA, Sur S, Raine-Fenning N. et al. Heparin for assisted reproduction: summary of a Cochrane review. Cochrane Database Syst Rev. 2013; 103 (01) 33-34
  • 128 Fluhr H, Spratte J, Ehrhardt J, Steinmüller F, Licht P, Zygmunt M. Heparin and low-molecular-weight heparins modulate the decidualization of human endometrial stromal cells. Fertil Steril 2010; 93 (08) 2581-2587
  • 129 Hardy K, Spanos S. Growth factor expression and function in the human and mouse preimplantation embryo. J Endocrinol 2002; 172 (02) 221-236
  • 130 Bose P, Black S, Kadyrov M. et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005; 192 (01) 23-30
  • 131 Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007; 22 (09) 2523-2527
  • 132 Dentali F, Grandone E, Rezoagli E, Ageno W. Efficacy of low molecular weight heparin in patients undergoing in vitro fertilization or intracytoplasmic sperm injection. J Thromb Haemost 2011; 9 (12) 2503-2506
  • 133 Noci I, Milanini MN, Ruggiero M, Papini F, Fuzzi B, Artini PG. Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study. Reprod Biomed Online 2011; 22 (06) 615-620
  • 134 Urman B, Ata B, Yakin K. et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod 2009; 24 (07) 1640-1647
  • 135 Seshadri S, Sunkara SK, Khalaf Y, El-Toukhy T, Hamoda H. Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2012; 25 (06) 572-584
  • 136 Potdar N, Gelbaya TA, Konje JC, Nardo LG. Adjunct low-molecular-weight heparin to improve live birth rate after recurrent implantation failure: a systematic review and meta-analysis. Hum Reprod Update 2013; 19 (06) 674-684
  • 137 Berker B, Taşkin S, Kahraman K, Taşkin EA, Atabekoğlu C, Sönmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study. Fertil Steril 2011; 95 (08) 2499-2502
  • 138 Grandone E, Villani M, Dentali F. et al. Low-molecular-weight heparin in pregnancies after ART—a retrospective study. Thromb Res 2014; 134 (02) 336-339
  • 139 Grandone E, Villani M, Tiscia GL. et al. Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience. PLoS One 2014; 9 (05) e97604
  • 140 Lodigiani C, Dentali F, Banfi E. et al. The effect of parnaparin sodium on in vitro fertilization outcome: a prospective randomized controlled trial. Thromb Res 2017; 159: 116-121
  • 141 Nap AW, Evers JL. Couples with infertility belong to a very vulnerable group, they should not be exploited. Hum Reprod 2007; 22 (12) 3262-3263 , author reply 3263
  • 142 Shaulov T, Sierra S, Sylvestre C. Recurrent implantation failure in IVF: a Canadian Fertility and Andrology Society Clinical Practice Guideline. Reprod Biomed Online 2020; 41 (05) 819-833
  • 143 American College of Obstetricians and Gynecologists (ACOG). Infertility workup for the women's health specialist: ACOG Committee Opinion, Number 781. Obstet Gynecol 2019; 133 (06) e377-e384
  • 144 American Society for Reproductive Medicine, American Board of Internal Medicine. Choosing Wisely: Ten things physicians and patients should question. 2015 . cited October 17, 2020. Accessed April 10, 2021 at: https://www.reproductivefacts.org/globalassets/asrm/asrm-content/learning–resources/choosing-wisely/asrm-choosing-wisely-list-questions.pdf
  • 145 Society for Maternal-Fetal Medicine, American Board of Internal Medicine. Choosing Wisely: Fifteen things physicians and patients should question. 2019 . cited October 19, 2020. Accessed April 10, 2021 at: https://www.choosingwisely.org/wp-content/uploads/2015/02/SMFM-Choosing-Wisely-List.pdf
  • 146 American College of Medical Genetics and Genomics, American Board of Internal Medicine. Choosing wisely: five things patients and providers should question. 2017 . cited October 19, 2020. Accessed April 10, 2021 at: https://www.choosingwisely.org/wp-content/uploads/2015/07/ACMG-Choosing-Wisely-List_Updated.pdf
  • 147 ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update 2013; 19 (05) 471-482
  • 148 Baglin T, Gray E, Greaves M. et al; British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149 (02) 209-220
  • 149 Bosch E, Broer S, Griesinger G. et al; ESHRE Guideline Group on Ovarian Stimulation. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open 2020; 2020 (04) a067
  • 150 Bates SM, Rajasekhar A, Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22) 3317-3359
  • 151 Nelson-Piercy C, MacCallum P, Mackillop L. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline No. 37a. (April 2015). cited November 16, 2020. Accessed April 10, 2021 at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf
  • 152 Nardo LG, El-Toukhy T, Stewart J, Balen AH, Potdar N. British Fertility Society Policy and Practice Committee. British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for good clinical practice. Hum Fertil (Camb) 2015; 18 (01) 2-15
  • 153 Chan W-S, Rey E, Kent NE. et al; VTE in Pregnancy Guideline Working Group, Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can 2014; 36 (06) 527-553
  • 154 National Institute for Health and Care Excellence (NICE). Fertility problems: assessment and treatment. (February 20, 2013). cited November 16, 2020. Accessed April 10, 2021 at: www.nice.org.uk/guidance/cg156
  • 155 Bates SM, Greer IA, Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: e691S-e736S
  • 156 Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 2008; 90: S188-S193
  • 157 American Board of Internal Medicine. Choosing wisely: promoting conversations between patients and clinicians. 2020 . cited October 19, 2020. Accessed April 10, 2021 at: https://www.choosingwisely.org